EUVIMEDEUVIMED entdecken
Crossref

A review of novel nanoformulations for treatment of dry eye disease and ocular surface inflammation

Alireza Nouralishahi, Navid Fazlinejad, Mohamad Saeid Hoseinzade Firozabadi, Saman Mohammadzadehsaliani, Rand Otbah Farqad, Haider Radhi Saud, Hadis Kheradjoo

Nanomedicine Journal · 2026-01 · 13 (1) · 30-53

DOI: 10.22038/nmj.2025.84709.2135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Journal, 2026-01. Verfasst von Alireza Nouralishahi und 6 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED) is a multifactorial condition frequently encountered in ocular disorders. DED not only causes ocular discomfort but also leads to damage to the cornea and conjunctiva. The topical route of drug administration is commonly used for treating ophthalmic diseases; however, its major limitation is the low ocular drug bioavailability, which typically amounts to less than 5%. This limitation arises due to the multiple permeation barriers between the tear film and the inner layers of the cornea, which hinder the achievement of therapeutic drug concentrations in ocular tissues. Researchers have significantly advanced in developing practical and safe drug delivery systems to address these challenges. These innovations have improved the penetration of medications through ocular barriers, enabled targeted delivery to specific cells and tissues, and enhanced the retention time, solubility of hydrophobic drugs in aqueous solutions, and overall bioavailability. Encapsulating drugs within nanoparticles has protected against degradation, further improving therapeutic efficacy. This review aims to explore various nanoformulations (e.g., liposomes, niosomes, suspensions, and emulsions) designed to enhance the ocular bioavailability of topically administered medications. A comprehensive DED inflammation overview focuses on the disease's etiology, clinical manifestations, and therapeutic approaches. It is anticipated that the development of advanced medication delivery systems will lead to improved management of DED shortly. The advancements discussed here may pave the way for creating novel, highly effective, and essential ocular nanosystems.

Schlagwörter

dry eye syndromesdrug delivery systemspharmaceutical formulationsnanotechnology

Zitieren

APA

Nouralishahi, A., Fazlinejad, N., Firozabadi, M. S. H., Mohammadzadehsaliani, S., Farqad, R. O., Saud, H. R., & Kheradjoo, H. (2026). A review of novel nanoformulations for treatment of dry eye disease and ocular surface inflammation. Nanomedicine Journal, 13(1), 30-53. https://doi.org/10.22038/nmj.2025.84709.2135

Vancouver

Nouralishahi A, Fazlinejad N, Firozabadi MSH, Mohammadzadehsaliani S, Farqad RO, Saud HR, et al. A review of novel nanoformulations for treatment of dry eye disease and ocular surface inflammation. Nanomedicine Journal. 2026;13(1):30-53. doi:10.22038/nmj.2025.84709.2135

BibTeX
@article{Nouralishahi2026,
  author = {Nouralishahi, Alireza and Fazlinejad, Navid and Firozabadi, Mohamad Saeid Hoseinzade and Mohammadzadehsaliani, Saman and Farqad, Rand Otbah and Saud, Haider Radhi and Kheradjoo, Hadis},
  title = {A review of novel nanoformulations for treatment of dry eye disease and ocular surface inflammation},
  journal = {Nanomedicine Journal},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {30--53},
  doi = {10.22038/nmj.2025.84709.2135}
}
Kostenlos starten →